Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
Holding SRPT?
Track your performance easily
SRPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$83.97 - $173.25
Previous Close$133.34
Volume777.55K
Average Volume (3M)976.72K
Market Cap
$12.74B
Enterprise Value$12.94B
Total Cash (Recent Filing)$1.20B
Total Debt (Recent Filing)$1.40B
Price to Earnings (P/E)110.8
Beta0.79
Next Earnings
Mar 04, 2025EPS Estimate
$1.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding95,519,650
10 Day Avg. Volume1,354,377
30 Day Avg. Volume976,722
Standard Deviation0.15
R-Squared0.08
Alpha0.00956
Financial Highlights & Ratios
Price to Book (P/B)8.67
Price to Sales (P/S)6.21
Price to Cash Flow (P/CF)-36.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.89
Enterprise Value/Gross Profit11.84
Enterprise Value/Ebitda68.87
Forecast
1Y Price Target
$183.79Price Target Upside37.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Sarepta Therapeutics News
Bulls Say, Bears Say
Bulls Say
Partnership And GrowthThe collaboration with ARWR addresses investor concerns about limited growth opportunities by providing new catalysts through diverse clinical programs.
Pipeline ExpansionThe new deal broadens the scope of SRPT's pipeline and strengthens its gene therapy platform, providing optionality for additional revenue streams beyond the DMD franchise.
Revenue GrowthSarepta is expected to drive revenue growth from Elevidys due to its market leadership and lack of meaningful near-term competitors.
Bears Say
Market And Investor SentimentInvestor concern is significant, particularly as management points to bottlenecks in conversion to commercial sales and peak sales to be years away.
Product DevelopmentThe decision to discontinue development of SRP-5051 and the overall PPMO franchise indicates a shift due to the asset's risk/benefit profile and evolving treatment landscape.
Sales And RevenueLight Elevidys sales and 2025 revenue guidance that just touches consensus on the top end caused a bit of a market freak out.
---
Ownership Overview
4.09% Insiders
29.29% Mutual Funds
31.39% Other Institutional Investors
14.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $83.97 and its highest was $173.25 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Currently, no data Available
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 73 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Nov 06, 2024. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of -$0.06 by $0.4.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is $1.54.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 95,519,650 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $0.34 in its last earnings report, beating expectations of -$0.06. Following the earnings report the stock price went down -5.9%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Among the largest hedge funds holding Sarepta Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Sarepta Therapeutics’s shares valued at 322M.
---
Sarepta Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$183.79 (37.84% Upside)
$183.79 (37.84% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 471.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $822.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
65.84%
12-Months-Change
Fundamentals
Return on Equity
12.27%
Trailing 12-Months
Asset Growth
15.76%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
---
SRPT Earnings Call
Q3 2024
0:00 / 0:00
---
SRPT Stock 12 Month Forecast
Average Price Target
$183.79
▲(37.84% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
BioMarin Pharmaceutical
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering SRPT
1 Year
1 Year Success Rate
18/21 ratings generated profit
1 Year Average Return
+19.81%
reiterated a buy rating 26 days ago
Copying Uy Ear's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +19.81% per trade.
---